For the first quarter of FY2027, net sales were 1,269 million yen, down 26.2% year over year. Operating income was 216 million yen, ordinary income 203 million yen, and net income attributable to owners of the parent 197.9 million yen. For the full year, the company disclosed a range of net sales of 5,000\u20136,000 million yen and operating income of 100\u2013600 million yen.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4584","jir_company_name":"Kidswell Bio Company","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-13","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4584-20260813-01.pdf","jir_short_summary":"For the first quarter of FY2027, net sales were 1,269 million yen, down 26.2% year over year. Operating income was 216 million yen, ordinary income 203 million yen, and net income attributable to owners of the parent 197.9 million yen. For the full year, the company disclosed a range of net sales of 5,000\u20136,000 million yen and operating income of 100\u2013600 million yen.","jir_summary":"### Performance overview\nThis quarter progressed with two main segments: a biosimilar business and a cell therapy business. Net sales declined year over year due to the post-launch competitive environment for products such as adalimumab, but profitability improved due to strengthened supply of APIs\/ formulations and cost-reduction measures. Operating income was 216 million yen, ordinary income 203.7 million yen, and net income attributable to owners of the parent 197.9 million yen, all above the previous year. The full-year outlook provides a range of net sales of 5,000\u20136,000 million yen and operating income of 100\u2013600 million yen.\n\n### Financial position and outlook\nTotal assets were 6,130,763 thousand yen, and net assets were 1,837,447 thousand yen. The company will continue efforts to strengthen its financial base, stabilize manufacturing and delivery plans, and enhance responses to exchange rate and cost fluctuations. R&D expenditure is expected to intensify from the second quarter onward. There are no significant events affecting the continuity of the company, while note-worthy attention is drawn to potential increases in funding needs.","jir_financial_highlights":"Net sales: 1,269,509\u5343\u5186 (YoY -26.2%)\nOperating income: 216,506\u5343\u5186 (YoY +17.3%)\nOrdinary income: 203,670\u5343\u5186 ( YoY +16.0%)\nNet income attributable to owners of the parent: 197,902\u5343\u5186 ( YoY +26.0%)\nTotal assets: 6,130,763\u5343\u5186 (vs end previous year +0.7%)\nNet assets: 1,837,447\u5343\u5186 (vs end previous year +11.1%)","jir_category":"","jir_hashtags":"#KidswellBio, #Earnings, #OutlookForThisTerm","jir_key_figures":"Net sales: 1,269,509\u5343\u5186\nOperating income: 216,506\u5343\u5186\nNet income attributable to owners of the parent: 197,902\u5343\u5186","jir_meta_title":"Kidswell Bio Q1 FY2027 Earnings Summary | Net sales down YoY","jir_meta_description":"Summary of Kidswell Bio's Q1 FY2027 earnings. Net sales of 1,269 million yen, operating income of 216 million yen, and net income of 197.9 million yen. Full-year outlook: net sales 5,000\u20136,000 million yen, operating income 100\u2013600 million yen.","jir_og_title":"Kidswell Bio Q1 Earnings Summary | Net sales 1,269 million yen","jir_og_description":"Key points of Kidswell Bio's Q1 FY2027 earnings. Net sales declined year over year, while operating income and net income increased. Full-year range disclosed.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":58797,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-103553","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n